We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Experimental flu Vaccine Bypasses Needles by Patricia Reaney

Experimental flu Vaccine Bypasses Needles by Patricia Reaney

Experimental flu Vaccine Bypasses Needles by Patricia Reaney

Experimental flu Vaccine Bypasses Needles by Patricia Reaney

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Experimental flu Vaccine Bypasses Needles by Patricia Reaney "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PowderMed Ltd has said that an experimental flu vaccine that blasts tiny particles into the skin instead of using a needle appears to be safe in people. 

The British-based company said it would move into bigger tests of its vaccine, which uses DNA from the flu virus to stimulate immunity. 

Writing in the journal Vaccine, PowderMed scientists said the vaccine stimulated an immune response in all 36 volunteers. 

Based on these results, PowderMed will start phase II studies using both annual and bird flu strains later this year. A finished product would still be years away. 

"Recent years have seen a number of new influenza vaccine approaches tested in animal model systems and in the clinic," said Dr. Hansi Dean, formerly with PowderMed and now with the International AIDS Vaccine Initiative. 

"However, this study is the first successful demonstration of immunogenicity of an influenza DNA vaccine in humans."

"DNA vaccines have the potential to significantly limit the burden of disease," added Dr. Clive Dix, chief executive officer of PowderMed.

"The advantage of a DNA-based approach is that the vaccines can be manufactured very rapidly and in large quantities, while yielding an efficacious immune response at low doses."

PowderMed's vaccine is produced by copying a gene from the virus - either the circulating influenza virus or the H5N1 avian flu virus - and enclosing it in tiny gold particles. 

It is delivered using an injector powered by concentrated helium gas, which pushes the particles into the skin.

The privately held firm is counting on some studies that suggest vaccines delivered right under the skin may produce better immunity than injected vaccines. 

And the company said the vaccine is stable and does not need to be refrigerated, or even administered by medical professionals, as are current vaccines.